Across TCGA pan-cancer cohorts, LCE3D mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LCE3D data layer compared with 20 for mass-spec protein and 2 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher LCE3D mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LCE3D expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.
HNSC and LSCC are the cancer types where LCE3D mass-spec protein most reproducibly stratifies survival.